Akebia Therapeutics Azioni (NASDAQ: AKBA)

Akebia Therapeutics (NASDAQ:AKBA) Azioni, Quote.MetaTitle.unusual-options

Akebia Therapeutics

Akebia Therapeutics Inc

AKBANK T/A/S S/ADR by Akbank Turk Anonim Sirketi

Akbank TAS

AKBANK T/A/S GDR 144A by Akbank Turk Anonim Sirketi

Absci

ADC Therapeutics

Altimmune

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Inventiva S.A. - American Depository Shares

Inventiva

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Kamada

Keros Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Monopar Therapeutics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Neurogene

Ocugen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Verastem

XOMA Royalty

Akebia Therapeutics (AKBA) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Comments

Akebia Therapeutics Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO